Source: Annual Congress 2002 - Asthma and COPD: pharmacology
Disease area: Airway diseases

Abstract

Objectives: To investigate the effects of 6 months therapy by slameterol and iprtropium bromide on lung function, effort abilities and dyspnoea in patients with COPD.
Material and methods: Open, randomised trial including 15 patients with symptomatic COPD comparing salmeterol (8 patients- group S) and iprtropium bromide (7 patients- group I). At every visit lung function (TLC, RV and RV%TLC) was measured by a pressure body plethysmograph, 6 minutes walking test was performed and results of 10 points subjective dyspnoea scale were taken.
Results: No differences between both groups in lung function parameters (TLC, RV and RV%TLC) were found, either before 6 months period of treatment, or after this period. Moreover, no improvement in lung function after 6 months therapy with both drugs was found (group S: visit 1: TLC: 6.49l RV: 3.50l; RV%TLC: 53.1; visit 2 – respectively - 6.38l; 3.33l; 50.8; group I – respectively - 6.86l; 4.58l; 64.4; 6.46l; 3.93l; 65.8). Significant improvement in 6 minutes walking test (group S: visit 1: 463,5 m., visit 2: 541,3; group A – respectively - 375,1; 453,4) and subjective dyspnoea scale (group S: visit 1: 4,75, visit 2: 2,87; group A – respectively -6,57; 5,28, significantly better in group S) was observed in both groups.

Rating:

Share or cite this content

Citations should be made in the following way:
T. Pitsch, A. Krzywiecki, B. Rogala (Zabrze, Poland). Six months treatment with salmeterol or ipratropium bromide improves effort tolerance and reduces dyspnoea but does not have any effect on lung function in COPD. Eur Respir J 2002; 20: Suppl. 38, 740

Member's Comments

No comment yet.

Related content which might interest you: Influence of higher than conventional doses of salbutamol or ipratropium bromide on bronchodilation induced by a regular treatment with tiotropium in patients suffering from stable COPD Source: Eur Respir J 2007; 30: Suppl. 51, 356s Year: 2007 Acute effect of formoterol, salmeterol, albuterol, oxitropium bromide and placebo on FEV1, inspiratory capacity and dyspnoea in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 380s Year: 2001 Lung function response to budesonide and ipratropium bromide in COPD patients who continue smoking Source: Eur Respir J 2002; 20: Suppl. 38, 245s Year: 2002 Effects of tiotropium bromide on bronchial obstruction and exercise tolerance in COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 213s Year: 2006 Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD Source: Eur Respir J 2001; 17: 1132-1137 Year: 2001 Nebulized formoterol improves airway function in COPD subjects receiving maintenance tiotropium Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Effects of tiotropium and salmeterol/fluticasone combination on lung hyperinflation, dyspnea and exercise tolerance in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 33s Year: 2006 The combination therapy with inhaled tiotropium bromide and transdermal tulobuterol in COPD improves the peripheral airway function Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010 Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients Source: Annual Congress 2010 - COPD: management Year: 2010 Effects of adding salmeterol to inhaled corticosteroids on lung function and quality of life in patients with mild persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006 Sleep architecture in COPD patients during salmeterol versus ipratropium bromide treatment Source: Eur Respir J 2004; 24: Suppl. 48, 113s Year: 2004 Improvement of dyspnoea following of six months treatment with tiotropium but not with salmeterol in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 26s Year: 2001 Aclidinium bromide improves resting lung function in patients with moderate to severe COPD Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010 A comparison of early bronchodilating responses of Salbutamol, Ipratropium bromide, and the combination of Ipratropium bromide-Salbutamol in stable patients with COPD or asthma Source: Eur Respir J 2002; 20: Suppl. 38, 246s Year: 2002 Replacing oxytropium with tiotropium significantly improves pulmonary function in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 213s Year: 2006 The improvements of lung function tests after formoterol administration in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 323s Year: 2004 Influence of tiotropium bromide on quantity of exacerbations and survival rate of COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 74s Year: 2007 Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Sleep architecture in COPD patients during salmeterol versus tiotropium bromide treatment Source: Eur Respir J 2006; 28: Suppl. 50, 199s Year: 2006 A comparison of bronchodilating response of salbutamol, ipratropium bromide and the combination of ipratropium-salbutamol in patients with stable chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 59s Year: 2001